Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
150
Millions of yenWording
Avoiding a definitive answer
How definitive the wording is.Recognition of Gain on Sale of Investment Securities (Extraordinary Income)
Subject Entity
日本製薬株式会社 (the filing company)
Target Locations / Products
2 listed securities held by the company
OccurrenceMay 2026 to March 2027 (period in which the gain on sale of investment securities is expected to arise)
This disclosure04/30/2026
Cause
To improve asset efficiency and strengthen the management foundation
Amount of Impact on Business Performance
¥150 million (estimated), extraordinary income
Accounting period in which recognized
Fiscal year ending March 2027
Impact on Earnings Forecast
The impact of changes in the amount and other related effects has already been incorporated into the earnings forecast for the fiscal year ending March 2027 disclosed today.
Outlook
The gain on sale of investment securities described above is scheduled to be recognized as extraordinary income in the fiscal year ending March 2027.
| Item | Details |
|---|---|
| Event name | Recognition of Gain on Sale of Investment Securities (Extraordinary Income) |
| Date of occurrence | May 2026 to March 2027 (period in which the gain on sale of investment securities is expected to arise) |
| Subject Entity | 日本製薬株式会社 (the filing company) |
| Target Locations / Products | 2 listed securities held by the company |
| Cause | To improve asset efficiency and strengthen the management foundation |
| Amount of Impact on Business Performance | ¥150 million (estimated), extraordinary income |
| Accounting period in which recognized | Fiscal year ending March 2027 |
| Impact on Earnings Forecast | The impact of changes in the amount and other related effects has already been incorporated into the earnings forecast for the fiscal year ending March 2027 disclosed today. |
| Outlook | The gain on sale of investment securities described above is scheduled to be recognized as extraordinary income in the fiscal year ending March 2027. |
Items this document does not state (16)
Date recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To improve asset efficiency and strengthen the management foundation.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.